Brief: Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
09/03/2026 11:19
March 9 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O: OLATOREPATIDE OBESITY TREATMENT LICENSED BY REGENERON DEMONSTRATES POSITIVE PHASE 3 RESULTS IN CHINESE PATIENTS REGENERON PHARMACEUTICALS INC - TO INITIATE GLOBAL PHASE 3 REGISTRATION PROGRAM FOR OLATOREPATIDE LATER THIS YEAR REGENERON PHARMACEUTICALS INC: PATIENTS TREATED WITH OLATOREPATIDE ACHIEVED UP TO 19% BODY-WEIGHT LOSS AT WEEK 48 REGENERON PHARMACEUTICALS INC - OLATOREPATIDE ACHIEVES UP TO 19% MEAN BODY-WEIGHT LOSS AT WEEK 48 REGENERON PHARMACEUTICALS INC - OLATOREPATIDE SHOWS FAVORABLE GASTROINTESTINAL TOLERABILITY WITH LOWER ADVERSE EVENT RATES Source text: ID:nGNXwW4gR Further company coverage: REGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)